December 28, 2023 — This was a year of great progress in obesity, and with that progress came frustrations and angst. So finding the best and worst of 2023 in obesity and health is actually quite an easy and interesting task. Let’s dig right in. #1 Best: Cardiovascular Outcomes Benefit Data for Semaglutide Above all else the landmark findings […]
November 13, 2023 — Nestled in the midst of a lot of good news last week was a nasty reminder of a persistent problem. It’s the fake line that people persist in drawing between obesity and other metabolic disease. Lilly did it (with consent from FDA) when they decided to put a different brand name on tirzepatide for obesity. […]
April 28, 2023 — Tirzepatide, marketed by Lilly under the Mounjaro brand, may be gliding toward an FDA approval for obesity later this year. A year ago, the first phase 3 study results for tirzepatide in obesity wowed us. Yesterday, Lilly revealed yet another impressive piece of the puzzle – impressive weight reduction in persons who have both obesity […]
April 26, 2023 — Insights surface when we take the time to listen to people living with obesity. Yesterday, Ro and the Obesity Action Coalition released results from a study of the thoughts and feelings people are having about obesity, weight loss, and the new GLP-1 medicines. There’s a lot to think about in these results – about motivations […]
October 29, 2020 — The New York Times seems to think that even our refrigerators are polarized. Let’s just say they have a bias that favors polarization. Political agitation is good for their business model – just as it is for Fox News. But seriously, the Times collected more than a thousand images of refrigerators through a mobile phone […]
